| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will present clinical data as a poster presentation at the upcoming 2025 American Society of Nephrology (ASN) Kidney Week, which will be held in Houston, TX on November 6-9, 2025.
"We look forward to returning to Kidney Week this year, where we will provide an update from our Phase 1b study of DISC-0974 in NDD-CKD patients with anemia," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "At the meeting, we plan to share data from all single and multiple-dose cohorts, including safety and tolerability, PK and pharmacodynamic markers."
The poster presentation will provide a data update from the Phase 1b, randomized, placebo-controlled study of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia. This study was designed to assess the safety, tolerability and pharmacokinetics of single ascending and multiple doses of DISC-0974, as well as measures of pharmacodynamic activity, including changes to hepcidin, iron, and hematologic parameters.
The abstract is now available through the ASN Kidney Week conference website. Pursuant to Disc Medicine practice, the abstract published today contains previously presented data, and new data and analyses are reserved for presentation at the conference.
Posted In: IRON
